|[April 15, 2014]
Research and Markets: Pediarix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/zb5v2n/pediarix)
has announced the addition of the "Pediarix
(Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis
to 2022" report to their offering.
Pediarix [Diphtheria and Tetanus Toxoids and Acellular Pertussis
Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine]
is GSK's pentavalent combination vaccine that offers protection against
infections caused by diphtheria, tetanus, pertussis, three subtypes of
poliovirus, and all known subtypes of HBV.
Overview of Hepatitis B disease, including epidemiology, etiology,
symptoms, diagnosis, pathology and treatment guidelines as well as an
overview on the competitive landscape.
Detailed information on Pediarix including product description, safety
and efficacy profiles as well as a SWOT analysis.
Sales forecast for Pediarix for the US from 2012 to 2022.
Sales information covered for the US.
Reasons to buy
Understand and capitalize by identifying products that are most likely
to ensure a robust return
Stay ahead of the competition by understanding the changing
competitive landscape for Hepatitis B
Effectively plan your M&A and partnership strategies by identifying
drugs with the most promising sales potential
Make more informed business decisions from insightful and in-depth
analysis of Pediarix performance
Obtain sales forecast for Pediarix from 2012-2022 in the US.
Key Topics Covered:
Tables & Figures
Vaccination Recommendations and Coverage Rates
For more information visit http://www.researchandmarkets.com/research/zb5v2n/pediarix
[ InfoTech Spotlight's Homepage ]